Sign in
4

Changes in Ownership

Aligos Therapeutics, Inc. Filed Acc 0001610717-24-000100

Options or other derivatives

  • Chief Medical Officer acquired 157,324 shares (grant or award)
  • Chief Medical Officer returned 370,626 shares (to the company)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
McClure Matthew W. Chief Medical Officer 2024-02-27 Returned to the company · Stock Option (Right to Buy) −255,626 0 D
McClure Matthew W. Chief Medical Officer 2024-02-27 Returned to the company · Stock Option (Right to Buy) −92,000 0 D
McClure Matthew W. Chief Medical Officer 2024-02-27 Returned to the company · Stock Option (Right to Buy) −23,000 0 D
McClure Matthew W. Chief Medical Officer 2024-02-28 Grant or award · Stock Option (Right to Buy) +75,183 75,183 D
McClure Matthew W. Chief Medical Officer 2024-02-28 Grant or award · Stock Option (Right to Buy) +65,713 65,713 D
McClure Matthew W. Chief Medical Officer 2024-02-28 Grant or award · Stock Option (Right to Buy) +16,428 16,428 D
Loading xslF345X05/form4.xml…